Viva Biotech operates a leading structure-based, integrated drug discovery platform, providing structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their preclinical stage innovative drug development. We actively combine the conventional cash-for-service (CFS) and unique equity-for-service (EFS) approaches to realize the combination of short-term drug-discovery services business (steady cash inflow) and long-term incubation investment (high-yield returns).

The CFS services cover the full spectrum of our customers’ needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Our patented core technologies, as well as our proprietary know-how which enables us to effectively shorten the average time required for drug discovery, are widely recognized by our customers. The EFS services focus on the initial creation and development of biotech startups across all indications and drug types. During the early stages of drug discovery, we can nurture and accelerate a startup’s growth from idea to clinical program.

Till June 30th, 2020, Viva Biotech has served 495 pharmaceutical customers worldwide, worked on over 1,300 independent drug targets, delivered approximately over 17,000 independent protein structures and incubated/invested 56 early-stage projects.